Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 242
Filter
1.
Semin Thromb Hemost ; 24(5): 431-5, 1998.
Article in English | MEDLINE | ID: mdl-9834009

ABSTRACT

Marked changes in the hemostasis system, especially increases in PAI-2, are observed during pregnancy and at delivery. This inhibitor is produced by placental trophoblasts and by macrophages. PAI-2 occurs in two forms, a LMW and a HMW form. LMW PAI-2 is intracellular, HMW PAI-2 is secreted. PAI-2 inhibits both u-PA and two-chain t-PA. PAI-2 seems to be involved in the processes of invasion and remodeling of fetal and uterine tissues. It may protect against premature placental separation and secure hemostasis at parturition. Excess levels of PAI-2 in amniotic fluid may protect membranes from premature rupture. An imbalance between fibrinolytic activators and inhibitors may also be related to intracranial hemorrhage in premature infants. During preeclampsia t-PA and PAI-1 levels are markedly increased in plasma, and in cases of intrauterine growth retardation, u-PA and PAI-2 levels are decreased. While elevated PAI-1 concentrations might be helpful markers of severity of preeclampsia, decreased PAI-2 levels seem to indicate decreased placental function and intrauterine growth retardation.


Subject(s)
Plasminogen Activator Inhibitor 2/blood , Pre-Eclampsia/blood , Pregnancy Complications, Cardiovascular/blood , Biomarkers , Female , Humans , Plasminogen Activator Inhibitor 1/blood , Pregnancy
2.
Int J Cancer ; 79(6): 588-95, 1998 Dec 18.
Article in English | MEDLINE | ID: mdl-9842966

ABSTRACT

Urokinase plasminogen activator (u-PA) plays a pivotal role in tissue degradation during tumor spread and metastasis. We have quantitated u-PA in tissue homogenates of 31 serous ovarian tumors and localized u-PA and its mRNA in tissue sections of 26 serous ovarian tumors. The content of u-PA was higher in malignant than in benign tumors, with the highest levels being found in poorly differentiated cancers. In tissue sections, the u-PA mRNA was hybridized with a radiolabeled RNA probe. Signals were almost exclusively found in the epithelium in benign and borderline tumors and in well-differentiated cancers. Poorly differentiated tumors and metastases exhibited prominent stromal expression of u-PA mRNA, whereas epithelial expression was weak or absent. Immuno-histochemical staining co-localized u-PA antigen with its mRNA in the epithelium of benign and borderline tumors and in well-differentiated cancers. Poorly differentiated malignant tumors showed extensive immunostaining in the epithelium in addition to stromal staining. The u-PA mRNA-expressing and u-PA-immunostained cells in the stroma were not tumor cells since no cells in the stroma were positive for cytokeratin. Poorly differentiated tumors had increased numbers of stromal macrophages (CD68), and they co-localized with some of the u-PA-positive cells. The presence of u-PA antigen and the absence of u-PA mRNA in tumor epithelium of poorly differentiated tumors and metastases together with the presence of u-PA mRNA in the stroma suggests production in stromal cells and subsequent binding to receptor sites in tumor cells.


Subject(s)
Ovarian Neoplasms/enzymology , Urokinase-Type Plasminogen Activator/metabolism , Cell Transformation, Neoplastic , Cystadenocarcinoma, Serous/enzymology , Female , Humans , Immunohistochemistry , Neoplasm Metastasis , Ovarian Neoplasms/pathology , RNA, Messenger/analysis , Stromal Cells/enzymology , Stromal Cells/pathology , Urokinase-Type Plasminogen Activator/genetics
3.
Fertil Steril ; 70(5): 821-6, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9806560

ABSTRACT

OBJECTIVE: To determine whether there is a difference in fibrinolytic compounds in endometriotic tissue, endometrium, peritoneal fluid (PF), and plasma from women with endometriosis and in endometrium and PF from healthy women. DESIGN: Prospective study. SETTING: Two university clinics. PATIENT(S): Regularly menstruating women with and without endometriosis. INTERVENTION(S): Tissue samples, PF, and blood were collected at surgery performed for clinical reasons. MAIN OUTCOME MEASURE(S): The antigen concentrations of plasminogen activators and plasminogen activator inhibitors (PAls) in tissue homogenates, PF, and plasma were assayed by ELISA. RESULT(S): The concentrations of urokinase plasminogen activator (u-PA) and PAI-1 were higher in endometrium from women with endometriosis than in endometrium from controls and even higher in endometriotic tissue than in endometrium from both groups. In PF, the concentration of PAI-2 was higher in women with endometriosis than in controls. CONCLUSION(S): The high concentrations of u-PA and PAI-1 in endometrium from women with endometriosis might facilitate implantation of endometrial cells and the high concentration in endometriotic tissue might contribute to their invasive growth. The inflammatory reaction may contribute to the high concentration of PAI-2.


Subject(s)
Ascitic Fluid/physiopathology , Endometriosis/physiopathology , Endometrium/physiology , Fibrinolysis/physiology , Adult , Case-Control Studies , Endometriosis/blood , Female , Humans , Middle Aged , Prospective Studies , Reference Values
4.
Inflammation ; 22(4): 341-51, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9675606

ABSTRACT

The concentrations of the specific activators (u-PA and t-PA) and the specific inhibitors (PAI-1 and PAI-2) of the fibrinolytic system were analyzed in the peritoneal fluid in women suffering from intra-abdominal adhesions, endometriosis or pelvic inflammatory diseases (PID). Peritoneal fluids were collected from ten women in whom a laparotomy was performed and an additional 108 in whom a laparoscopy was carried out. In comparison with the normal control patients all activators and inhibitors were significantly increased in cases of PID and when a second-look laparoscopy was performed one week after laparotomy with adhesiolysis. At laparoscopies, when adhesions were verified, u-PA in the peritoneal fluid was significantly increased and in cases of endometriosis PAI-2 was significantly reduced. The start of a laparotomy in order to remove adhesions, initiates a process, resulting in a significant increase of PAI-2 antigen in the pelvic fluid. The results imply that the fibrinolytic system is comprehensively activated in the peritoneal cavity during ongoing inflammatory reaction, and after adhesiolysis. The increase in plasminogen activators in the peritoneal fluid in established cases of pelvic adhesions or endometriosis may indicate that the fibrinolytic system is continuously active to inhibit the further formation of adhesions.


Subject(s)
Ascitic Fluid/metabolism , Endometriosis/metabolism , Fibrinolysis , Pelvic Inflammatory Disease/metabolism , Case-Control Studies , Female , Humans , Plasminogen Activator Inhibitor 1/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Tissue Adhesions/etiology , Tissue Adhesions/metabolism , Tissue Plasminogen Activator/metabolism , Urokinase-Type Plasminogen Activator/metabolism
5.
Am J Obstet Gynecol ; 176(2): 457-60, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9065198

ABSTRACT

OBJECTIVE: Resistance to activated protein C is an inherited mutation of the coagulation factor V gene, a major factor predisposing to thromboembolic events. The purpose of this study was to investigate the occurrence of heterozygote and homozygote activated protein C resistance in women with preeclampsia. STUDY DESIGN: Activated protein C resistance and protein C and antithrombin III levels were determined in women (n = 50) with a history of preeclampsia and in controls (50 women with a previous normal pregnancy). The mutation of the factor V gene was analyzed. RESULTS: Activated protein C resistance was found in 22% of women with previous preeclampsia compared with 10% among controls. Two women in the previous preeclampsia group had a homozygote mutation of factor V; the others were heterozygous. There was a significant difference in the activated protein C ratio between women with previous preeclampsia and the control group, 2.6 +/- 0.4 versus 3.1 +/- 0.5 (p = 0.04). None of the women had protein C or antithrombin III deficiency. CONCLUSION: The results indicate that activated protein C resistance may be a contributory factor in the pathogenesis of preeclampsia.


Subject(s)
Factor V/genetics , Mutation , Pre-Eclampsia/blood , Protein C/genetics , Antithrombin III/analysis , Drug Resistance/genetics , Female , Heterozygote , Homozygote , Humans , Pregnancy
6.
Acta Paediatr ; 86(1): 111-3, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9116413

ABSTRACT

OBJECTIVE: To compare the plasminogen activators (tPA, uPA) and their inhibitors (PAI-1, PAI-2) at different gestational ages, related to levels in women at term and non-pregnant women. METHODS: Blood samples were obtained by puncture of the umbilical cord vein, in gestational weeks 39-40 (n = 21), 30-32 (n = 15), and 27-29 (n = 9). Analyses of PA and PAI antigen concentrations and of PAI-1 activity were performed. RESULTS: The mean tPA antigen level in term newborn infants was 14.5 micrograms/l compared to the premature newborns (7.0 micrograms/l), women at term (7.5 micrograms/l) and non-pregnant women (2.3 micrograms/l). PAI-1 activity and PAI-2 antigen concentrations were also higher in term newborn than in premature infants. CONCLUSIONS: The plasma levels of the plasminogen activators and inhibitors are higher in term newborn compared with premature newborn infants, reflecting maturation of protein synthesis.


Subject(s)
Infant, Newborn/blood , Infant, Premature/blood , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activator Inhibitor 2/blood , Plasminogen Activators/blood , Female , Fetal Blood/chemistry , Gestational Age , Humans , Pregnancy/blood
7.
Scand J Clin Lab Invest ; 56(6): 491-6, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8903110

ABSTRACT

The plasminogen activator inhibitor type 2 (PAI-2) is present in its high molecular weight, glycosylated form in pregnancy plasma. When the protein was purified from retroplacental blood by immunoaffinity chromatography on a PAI-2 antibody column and the retained material was further fractionated by gel filtration chromatography, it was always contaminated by apolipoprotein A1, the latter protein being identified by its N-terminal sequence, molecular weight in SDS-PAGE and immunological properties. The co-purification of the two proteins seemed to indicate a strong affinity between them, suggesting apolipoprotein A1 to be a carrier protein for this PAI-2 form. Further investigation to check this hypothesis showed that the binding of apolipoprotein A1 to the immunoaffinity support was PAI-2-independent and caused by a general surface affinity. This finding was corroborated by a study of the microtitre plate binding properties of the proteins. Pure, high molecular weight PAI 2 did not bind to apolipoprotein A1-coated wells, but the latter protein bound to coated as well as to uncoated wells. Thus, there is no evidence for a specific binding between the two proteins.


Subject(s)
Apolipoprotein A-I/metabolism , Plasminogen Activator Inhibitor 2/metabolism , Apolipoprotein A-I/blood , Apolipoprotein A-I/isolation & purification , Female , Humans , Placenta/blood supply , Plasminogen Activator Inhibitor 2/blood , Pregnancy , Protein Binding/physiology
8.
Stroke ; 27(6): 1066-71, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8650716

ABSTRACT

BACKGROUND AND PURPOSE: Abnormal endogenous fibrinolytic activity may be a risk factor for stroke. Since the possible variation of tissue-type plasminogen activator (TPA) antigen and plasminogen activator inhibitor-1 (PAI-1) antigen concentrations over time after stroke has been rarely studied, it was examined in plasma from stroke patients in the acute and convalescent phases of the disease and in a control group. METHODS: Plasma concentrations of TPA and PAI-1 were determined in 135 stroke patients and in 77 control subjects. All but 4 patients were examined within 7 days after stroke onset, and 32 patients and 18 control subjects were reexamined 2 to 4 years later. RESULTS: In the acute phase, stroke patients had significantly higher TPA (median, 10 micrograms/L) and PAI-1 (median, 14 micrograms/L) antigen concentrations, compared with control subjects (median values, 6 micrograms/L [P = .0001] and 8 micrograms/L [P < .01], respectively); TPA levels were higher in both the cerebral infarction (n = 122) and cerebral hemorrhage (n = 12) subgroups, whereas PAI-1 levels were higher in the cerebral infarction subgroup only. Stepwise logistic regression analysis (with correction for age, sex, history of hypertension, diabetes mellitus, and heart disease) showed TPA antigen level to be an independent discriminator between the cerebral infarction subgroup and control subjects (P = .0001), whereas the corresponding difference for PAI-1 antigen levels just failed to reach significance (P = .05). TPA antigen levels were correlated with concentrations of serum cholesterol (Spearman's rho = 0.15; P < .05), serum triglyceride (rho = 0.33; P = .0001), and plasma homocysteine (rho = 0.19; P < .01). PAI-1 antigen levels were correlated with serum triglyceride levels only (rho = 0.41; P = .0001). At reexamination after 2 to 4 years, neither TPA nor PAI-1 levels had changed significantly from the baseline values. CONCLUSIONS: In stroke patients, high TPA antigen concentrations may indicate an activation of the fibrinolytic system or may be due to a delayed clearance of TPA complexed with inhibitors. High PAI-1 antigen concentrations in patients with cerebral infarction represent increased fibrinolytic inhibition. The findings in this longitudinal study suggest that TPA and PAI-1 antigen concentrations both differ little between the acute and convalescent phases after stroke.


Subject(s)
Cerebrovascular Disorders/blood , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activators/blood , Serine Proteinase Inhibitors/blood , Tissue Plasminogen Activator/blood , Acute Disease , Adult , Aged , Aged, 80 and over , Cerebral Hemorrhage/blood , Cerebral Infarction/blood , Cholesterol/blood , Diabetes Complications , Female , Fibrinolysis , Follow-Up Studies , Heart Diseases/complications , Homocysteine/blood , Humans , Hypertension/complications , Logistic Models , Longitudinal Studies , Male , Middle Aged , Risk Factors , Triglycerides/blood
9.
Maturitas ; 24(1-2): 43-50, 1996 May.
Article in English | MEDLINE | ID: mdl-8794433

ABSTRACT

OBJECTIVES: To assess the effect of estrogen replacement therapy on hemostatic risk factors for cardiovascular disease (CVD) in postmenopausal women during 2 years of treatment. METHODS: In an open prospective study, patients (n = 42) were investigated before and during 2 years of treatment, and compared to an untreated postmenopausal control group (n = 18) followed during the same period, healthy premenopausal women (n = 20) being included as a reference group for premenopausal values. The patients underwent treatment with transdermal 17 beta-estradiol (E2) (50 micrograms/24 h), oral medroxyprogesterone acetate (5 mg/day) being added for 12 days every second month. RESULTS: After 2 years of treatment there was a significant increase in t-PA antigen (P = 0.01) and a significant decrease in F VII antigen (P = 0.01). PAI-1 antigen concentrations decreased slightly. Fibrinogen concentrations were already significantly decreased at 3-month follow-up (P = 0.01), and were still low after 2 years. By contrast, at 2-year follow-up the postmenopausal control group manifested significant increases in F VII and PAI-1 antigen and slight increases in fibrinogen, which resulted in significant differences between patients and controls. Regression analysis showed the increase in the serum estradiol concentrations to be inversely correlated to the decreases in the plasma concentrations of F VII antigen (r = -0.34, P = 0.001) and fibrinogen (r = -0.35, P = 0.001). There were no changes in AT III or protein C in any group. CONCLUSIONS: The increase in serum estradiol concentrations due to replacement therapy did not adversely affect the studied components of the fibrinolytic and protein C defense system against thrombosis, and resulted in beneficial decreases in F VII antigen and fibrinogen. These findings may help to explain the beneficial effects of estrogen replacement therapy in terms of protection from cardiovascular disease.


Subject(s)
Estradiol/therapeutic use , Estrogen Replacement Therapy , Heart Diseases/prevention & control , Hemostasis/drug effects , Administration, Cutaneous , Administration, Oral , Adult , Antithrombin III/analysis , Estradiol/administration & dosage , Estradiol/blood , Factor VII/analysis , Female , Fibrinogen/analysis , Fibrinolysis/drug effects , Follow-Up Studies , Humans , Medroxyprogesterone Acetate/administration & dosage , Medroxyprogesterone Acetate/therapeutic use , Middle Aged , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activators/blood , Postmenopause , Progesterone Congeners/administration & dosage , Progesterone Congeners/therapeutic use , Prospective Studies , Protein C/analysis , Regression Analysis , Risk Factors , Serine Proteinase Inhibitors/blood , Tissue Plasminogen Activator/blood
10.
J Periodontal Res ; 31(4): 271-7, 1996 May.
Article in English | MEDLINE | ID: mdl-8814598

ABSTRACT

Gingival inflammatory symptoms are aggravated during pregnancy. In vitro studies suggest a hormonal influence on the plasminogen activator inhibitor type 2 (PAI-2), and a disturbed balance of the fibrinolytic system could help to explain pregnancy gingivitis. Gingival crevicular fluid (GCF) was sampled in 14 women in pregnant and post-pregnant states. The gingival condition was assessed by the gingival index of Løe & Silness (GI) and the amount of bacterial plaque by the plaque index of Silness & Løe (PI). The ratio of sites with gingivitis to sites with bacterial plaque was calculated (G/P-ratio). Antigen levels of tissue plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA), plasminogen activator inhibitors type 1 (PAI-1) and PAI-2 in GCF were determined with ELISAs and 17 beta-oestradiol and progesterone in serum with radioimmunoassays. For each individual the differences (delta) in hormone levels and PAs and PAIs between pregnancy and post-pregnancy were calculated. Based on differences in G/P-ratio between pregnancy and post-pregnancy, subgrouping was done into a high-reacting and a low-reacting group. For the total group, the mean G/P-ratio was 2.0 during and 1.2 after pregnancy (p = 0.064). A statistically significant correlation between delta progesterone and delta PAI-2 was noted: the higher delta progesterone, the lower delta PAI-2. No other significant correlations between hormone levels and components of the fibrinolytic system were found. For the total group of women, the concentrations of PAI-2, PAI-1 and t-PA were significantly higher during than after pregnancy. The individuals in the high-reacting group, however, showed a lower or unchanged production of PAI-2 during pregnancy, while those in the low-reacting group showed a greatly increased production. The lower inhibitory capacity in terms of a low production of PAI-2 during pregnancy in women with a higher inflammatory reaction indicates that the components of the fibrinolytic system may be involved in the development of pregnancy gingivitis and implies that PAI-2 serves as an inhibitor of importance for tissue proteolysis. The present finding contributes to the explanation of pregnancy gingivitis.


Subject(s)
Gingival Crevicular Fluid/chemistry , Gingivitis/physiopathology , Plasminogen Activator Inhibitor 2/analysis , Pregnancy Complications/physiopathology , Adult , Dental Plaque Index , Enzyme-Linked Immunosorbent Assay , Estradiol/blood , Female , Fibrinolysis , Gingivitis/blood , Gingivitis/metabolism , Humans , Periodontal Index , Plasminogen Activator Inhibitor 1/analysis , Plasminogen Activator Inhibitor 2/physiology , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/metabolism , Progesterone/blood , Protease Inhibitors/analysis , Tissue Plasminogen Activator/analysis , Urokinase-Type Plasminogen Activator/analysis
13.
Br J Obstet Gynaecol ; 102(11): 913-7, 1995 Nov.
Article in English | MEDLINE | ID: mdl-8534629

ABSTRACT

OBJECTIVE: To compare the effect of Kabi 2161 (a prodrug of tranexamic acid) and placebo on the reduction of menstrual blood loss in women suffering from idiopathic menorrhagia and to evaluate tolerance and effectiveness in a two-dose regimen. DESIGN: A randomised, double blind parallel group study using double dummy technique. SETTING: The departments of gynaecology at three medical centres in Sweden. SUBJECTS: Ninety-one outpatients visiting the gynaecological clinics from March 1991 to May 1992 were randomised into the study; 68 women fulfilled the study. INTERVENTIONS: Two run-in cycles, followed by administrations of Kabi 2161 (600 mg) tablets (1 four times daily or 2 twice daily) or placebo for the first five days of three menstrual cycles. MAIN OUTCOME MEASURES: Objective measurement of the change in menstrual blood loss during the treatment periods compared with menstrual blood loss during the run-in periods. RESULTS: A statistically significant reduction of menstrual blood loss was found for each treatment group, compared with the placebo group (P < 0.001). The mean reduction with 95% confidence interval (CI) was 33% (24-40) in the group treated with 1 four times daily and 41% (33-49) in the group treated 2 twice daily. The difference between the treated groups in reduction of menstrual blood loss is not significant. No significant differences were found in the frequencies of reported unwanted events during run-in and during treatment between the different treatment groups. There were also no significant differences between the treatment groups and the placebo group. CONCLUSION: Kabi 2161 in a dosage of 2.4 g per day gave a statistically significant reduction in objectively measured menstrual blood loss in a two (41%) as well as in a four (33%) dosage regimen compared with placebo. Frequency of unwanted events did not differ from those during run-in or from those in the placebo group. The optimal daily dosage needs to be further evaluated in a dose titration study.


Subject(s)
Antifibrinolytic Agents/therapeutic use , Menorrhagia/drug therapy , Adult , Aged , Antifibrinolytic Agents/adverse effects , Blood Pressure , Double-Blind Method , Female , Humans , Menstrual Hygiene Products , Middle Aged , Treatment Outcome
14.
Int J Cancer ; 61(4): 542-7, 1995 May 16.
Article in English | MEDLINE | ID: mdl-7759160

ABSTRACT

Malignant cells possess a high degree of proteolytic activity in which the plasminogen activator system plays an important role. An increased expression of urokinase type plasminogen activator (uPA) is of significance for degradation of the extracellular tumor matrix, facilitating invasiveness and growth. Inhibition of the active site of uPA makes it possible to evaluate the significance of uPA in tumor growth. We report here experiments on a uPA-producing human prostate xenograft (DU 145) using a competitive inhibitor of uPA, p-aminobenzamidine. In vitro experiments with DU 145 cells showed that p-aminobenzamidine caused a dose-dependent inhibition of uPA activity. DU 145 cells were inoculated s.c. in SCID mice and, once tumors were established, treatment with p-aminobenzamidine added to drinking water was started and lasted for 23 days. Mice receiving 250 mg/kg/day of p-aminobenzamidine showed a clear decrease in tumor-growth rate compared to the non-treated mice, resulting in 64% lower final tumor weight. In addition, uPA-antigen levels in the membrane fractions of DU 145 tumors from p-aminobenzamidine-treated mice were found to be decreased by 59%. We also show that p-aminobenzamidine has an anti-proliferative effect in cell culture at low cell number, correlating with a dose-dependent decrease in uPA production. In conclusion, we show that a low-molecular-weight uPA-inhibitor, p-aminobenzamidine, has a growth-inhibitory effect on a solid uPA-producing tumor.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/enzymology , Benzamidines/pharmacology , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/enzymology , Urokinase-Type Plasminogen Activator/antagonists & inhibitors , Adenocarcinoma/pathology , Animals , Cell Division/drug effects , Dose-Response Relationship, Drug , Humans , Male , Mice , Mice, SCID , Prostatic Neoplasms/pathology , Tumor Cells, Cultured/drug effects , Urokinase-Type Plasminogen Activator/metabolism
15.
Semin Thromb Hemost ; 21(4): 364-70, 1995.
Article in English | MEDLINE | ID: mdl-8747699

ABSTRACT

Coumarin derivatives and anticonvulsants administered during pregnancy enter the fetal circulation, interfering with the action of vitamin K. Vitamin K plays a crucial part in the gamma-carboxylation of glutamic acid residues of the vitamin K-dependent coagulation factors prothrombin, FVII, FIX, and FX. Other vitamin K-dependent proteins in the coagulation cascade are protein C and protein S. Vitamin K-dependent bone proteins are osteocalcin and gamma-carboxyglutamate matrix protein. Administration of coumarol derivatives results in under carboxylation of the vitamin K-dependent proteins. Anticoagulation therapy with warfarin is followed by an increased risk of embryopathy, which has been shown to be greatest between gestational weeks 6 and 12. Administration of warfarin is also followed by an increased risk both of fetal intraventricular hemorrhage, and of cerebral microbleedings, which may result in microencephaly and mental retardation. Treatment with coumarol derivatives should therefore be avoided during pregnancy, even in pregnant women with artificial heart valves, and replaced by heparin. Hemorrhage in the newborn related to the use of anticonvulsant drugs during pregnancy occurs very early within the first 24 hours, probably due to increased degradation of vitamin K. Transplacental administration of vitamin K has been shown to prevent neonatal hemorrhage induced by maternal anticonvulsant therapy. Prophylactic administration of vitamin K, especially by intramuscular injection, has been reported to be associated with an increased risk of childhood cancer. However, subsequent extensive studies have yielded no evidence of any relationship between prophylactic vitamin K administration and the occurrence of childhood cancer.


Subject(s)
Abnormalities, Drug-Induced/etiology , Anticoagulants/adverse effects , Anticonvulsants/adverse effects , Coumarins/adverse effects , Fetal Diseases/chemically induced , Pregnancy Complications/drug therapy , Prenatal Exposure Delayed Effects , Vitamin K Deficiency/chemically induced , Vitamin K/physiology , Anticoagulants/pharmacokinetics , Anticonvulsants/pharmacokinetics , Blood Coagulation Factors/metabolism , Child , Cohort Studies , Coumarins/pharmacokinetics , Epilepsy/drug therapy , Female , Hemorrhage/chemically induced , Humans , Infant, Newborn , Maternal-Fetal Exchange , Neoplasms/chemically induced , Neoplasms/epidemiology , Pregnancy , Protein Processing, Post-Translational , Sweden/epidemiology , Thrombosis/drug therapy , United Kingdom/epidemiology , Vitamin K/adverse effects , Vitamin K/therapeutic use , Vitamin K Deficiency/embryology , Vitamin K Deficiency/prevention & control
16.
Am J Obstet Gynecol ; 171(1): 60-4, 1994 Jul.
Article in English | MEDLINE | ID: mdl-8030735

ABSTRACT

OBJECTIVE: Our purpose was to study the plasma concentrations of the plasminogen activator of urokinase type and its specific inhibitor of placental type in pregnancies complicated by hypertension or fetal growth retardation. STUDY DESIGN: Consecutive patients with pregnancy-induced hypertension (n = 17), mild preeclampsia (n = 17), severe preeclampsia (n = 19), and intrauterine growth retardation (n = 19) were studied. Blood samples were obtained just before delivery (mean 2 days). Women with normal pregnancies (n = 40), longitudinally followed between the tenth and fortieth gestational weeks, served as a control group. RESULTS: The plasma concentrations of the urokinase type antigen were significantly lower in women with severe preeclampsia or intrauterine growth retardation than those in women with normal pregnancies (p < 0.001). In all four groups with complicated pregnancies the antigen concentrations of the urokinase type and its inhibitor were significantly correlated with both placental weight and birth weight. CONCLUSIONS: The plasma concentration of the urokinase type antigen would appear to reflect placental function, and both the antigen and its inhibitor concentrations are correlated with placental and fetal growth.


Subject(s)
Fetal Growth Retardation/blood , Hypertension/blood , Placenta/physiopathology , Plasminogen Activator Inhibitor 2/blood , Pre-Eclampsia/blood , Pregnancy Complications, Cardiovascular/blood , Urokinase-Type Plasminogen Activator/blood , Birth Weight , Case-Control Studies , Female , Fetal Growth Retardation/pathology , Humans , Hypertension/pathology , Infant, Newborn , Placenta/pathology , Placental Insufficiency , Pre-Eclampsia/pathology , Pregnancy , Pregnancy Complications, Cardiovascular/pathology
17.
Int J Fertil Menopausal Stud ; 39(3): 133-9, 1994.
Article in English | MEDLINE | ID: mdl-7920748

ABSTRACT

OBJECTIVE: Steroid hormones, especially estrogens, are known to affect hemostatic risk factors for thromboembolism, cardiovascular disease, and stroke. We examined these risk factors during depression of the serum estradiol concentration by a GnRH analogue. DESIGN: Patients were treated with a GnRH analogue, goserelin (Zoladex), 3.6 mg/inj monthly, for a period of 6 months. Blood samples were collected during and after treatment and in a control group. In ten patients a blood sample was also drawn before treatment. Measurements were made of serum estradiol, and the plasma concentrations of tissue-type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor (PAI-1) antigen, antithrombin III (AT III) and protein C activity, factor VII (FVII) antigen, and fibrinogen. SETTING: Outpatient clinics at the Departments of Obstetrics and Gynecology at two university hospitals in southern Sweden. PARTICIPANTS: Twenty-seven women with endometriosis were consecutively included. A control group comprised 20 women with normal menstrual cycles. MAIN OUTCOME MEASURES: The concentrations of the hemostatic components during depression of the serum estradiol concentrations, as compared to those during normal ovulatory cycles. RESULTS: Serum estradiol concentrations during treatment were comparable to those of postmenopausal women (mean, 23.2 pmol/L), and both AT III and protein C activity were significantly increased (P < .005 and P < .02, respectively). As compared to controls, plasma concentrations of PAI-1 and t-PA of patients were significantly higher both during and after treatment. In the subgroup also studied prior to treatment, there were no differences in hemostatic components, when comparing pretreatment and posttreatment values. CONCLUSIONS: Treatment with this type of GnRH analogue for 6 months is safe with regard to its effect on hemostatic risk factors. The similar responses of t-PA and its inhibitor, PAI-1, to alterations in estrogen levels as well as inflammatory reactivity presumably constitute a balance mechanism preserving fibrinolytic defenses.


Subject(s)
Endometriosis/drug therapy , Goserelin/adverse effects , Hemostasis/drug effects , Thromboembolism/etiology , Adult , Antithrombin III/analysis , Endometriosis/blood , Estradiol/blood , Factor VII/analysis , Female , Fibrinogen/analysis , Goserelin/therapeutic use , Humans , Middle Aged , Plasminogen Activator Inhibitor 1/blood , Plasminogen Activators/blood , Protein C/analysis , Risk Factors , Thromboembolism/epidemiology
18.
J Perinat Med ; 22(3): 181-8, 1994.
Article in English | MEDLINE | ID: mdl-7823257

ABSTRACT

Urokinase (u-PA) dissolves and removes fibrin deposits in the renal secretory pathways in various renal diseases. During pregnancy nephropathy creates a problem in preeclampsia and diabetes, but the underlying mechanism of glomerular damage is different. Preeclamptic nephropathy is characterized as 'glomerular endotheliosis' with hypertrophy of the intracapillary cells, and diabetic nephropathy as 'glomerulosclerosis' with hyaline deposits. The role of fibrin deposition for the etiology of renal damage in preeclampsia is controversial. Changes of the urinary secretion of u-PA may reflect the type of glomerular damage. Our hypotheses were that renal insufficiency is associated with a low u-PA activity in both conditions, and that severe disease is parallel to declining concentrations of u-PA. We compared the glomerular filtration rate, S-Creatinine and S-Urate with urinary u-PA excretion in 24 hypertensive and 20 diabetic pregnant women. In diabetic patients, a low u-PA concentrations was associated with an impaired renal function. In hypertensive pregnancy, the u-PA excretion did not reflect the severity of the hypertensive disease or renal function. No association was found between u-PA excretion and renal function post partum in any group. We conclude that renal urokinase activity plays a role for renal function in diabetic but not in hypertensive pregnancy.


Subject(s)
Hypertension/physiopathology , Kidney/physiopathology , Pregnancy Complications, Cardiovascular/physiopathology , Pregnancy in Diabetics/physiopathology , Urokinase-Type Plasminogen Activator/urine , Female , Follow-Up Studies , Glomerular Filtration Rate , Humans , Hypertension/metabolism , Pregnancy , Pregnancy Complications, Cardiovascular/metabolism , Pregnancy in Diabetics/metabolism , Proteinuria/physiopathology , Proteinuria/urine
19.
Eur J Cancer ; 30A(9): 1302-9, 1994.
Article in English | MEDLINE | ID: mdl-7999418

ABSTRACT

We quantitated urokinase and tissue plasminogen activator (u-PA, t-PA), plasminogen activator inhibitor 1 and 2 (PAI-1, PAI-2), and fibrinolytic activity in peripheral blood (PB), tumour blood (TB), peritoneal/ascitic fluid (PAF) and cystic fluid (CF) from 104 patients with benign and 36 patients with malignant ovarian tumours, and in peripheral blood from 62 healthy controls. PB levels of u-PA were higher in patients with benign and malignant tumours than in controls. High concentrations of u-PA were found in CF, but not in TB, suggesting that u-PA is released by the tumour tissue, but not by the tumour vasculature. PB levels of t-PA were higher in both tumour groups than in controls. Increased levels of t-PA were found in TB, but not in CF, indicating that t-PA is released by the tumour vasculature, but not by the tumour tissue. PB levels of PAI-1 were higher in patients with both benign and malignant tumours than in controls. High levels of PAI-1 were present in both TB and CF from malignant tumours, suggesting that PAI-1 is released from the tumour vasculature as well as the tumour tissue. Elevated concentrations of PAI-2 were found in CF, but not in TB, indicating release from the tumour tissue, but not from the vasculature. High levels of t-PA, PAI-1 and PAI-2 were found in PAF of malignant tumours, and resorption from this compartment may explain elevated PB levels in patients with ascites. None of the PAs/PAIs proved useful as a PB marker for detection of early stage ovarian cancer. However, an index based on PAF levels of t-PA and PAI-1 discriminated between malignant and benign ovarian cysts in the absence of ascites. In addition, our study stresses the importance of including patients with benign tumours as well as healthy controls when markers for malignant tumours are evaluated.


Subject(s)
Biomarkers, Tumor/analysis , Ovarian Neoplasms/chemistry , Plasminogen Activators/analysis , Plasminogen Inactivators/analysis , Ascitic Fluid/chemistry , Female , Fibrinolysis , Humans , Middle Aged , Ovarian Neoplasms/blood , Plasminogen Activator Inhibitor 1/analysis , Plasminogen Activator Inhibitor 2/analysis , Urokinase-Type Plasminogen Activator/analysis
20.
Thromb Haemost ; 70(2): 238-40, 1993 Aug 02.
Article in English | MEDLINE | ID: mdl-8236125

ABSTRACT

Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e.g., menorrhagia and gastro-intestinal haemorrhage), and to prevent bleeding at surgery, in cases of abruptio placentae and general haemorrhage. As AMCA stabilises preformed clots and prolongs their dissolution, it has been debated whether treatment with AMCA might predispose to thrombosis by depressing the fibrinolytic system. Pregnant women constitute a group with low fibrinolytic capacity and an increased frequency of thrombosis further increased after Caesarean section, and are thus more likely to be susceptible to antifibrinolytic therapy. We therefore carried out a retrospective analysis of the case records of 2,102 patients with various bleeding disorders during pregnancy. Of the 256 patients treated with AMCA (mean duration of treatment, 46 days), 169 were delivered by Caesarean section. Of the remaining 1,846 patients (i.e., controls), 443 were delivered by Caesarean section. The relationship between the use of AMCA and the occurrence of thrombo-embolism was calculated with 95% confidence limits. Of the AMCA treated group (n = 256), two patients--one of whom belonged to the Caesarean section subgroup (n = 168)--had pulmonary embolism. Of the controls (n = 1,846), three patients had deep vein thrombosis and one had pulmonary embolism, all four cases belonging to the Caesarean section subgroup (n = 443). Thus, the findings in this high risk group of women with complicated pregnancies, frequently entailing delivery by Caesarean section, provided no evidence of any thrombogenic effect of AMCA.


Subject(s)
Abruptio Placentae/drug therapy , Hemorrhage/drug therapy , Pregnancy Complications, Hematologic/chemically induced , Pregnancy Complications, Hematologic/drug therapy , Thromboembolism/chemically induced , Tranexamic Acid/therapeutic use , Case-Control Studies , Cesarean Section/statistics & numerical data , Female , Humans , Incidence , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Pregnancy , Pregnancy Complications, Hematologic/epidemiology , Puerperal Disorders/chemically induced , Puerperal Disorders/epidemiology , Pulmonary Embolism/chemically induced , Pulmonary Embolism/epidemiology , Pulmonary Embolism/etiology , Retrospective Studies , Risk Factors , Sweden/epidemiology , Thromboembolism/epidemiology , Thromboembolism/etiology , Thrombophlebitis/chemically induced , Thrombophlebitis/epidemiology , Thrombophlebitis/etiology , Tranexamic Acid/administration & dosage , Tranexamic Acid/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...